# US 2015/0105402 A1 · Trazodone and trazodone hydrochloride in purified form

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105402 A1
- Document ID: US20150105402A1
- Status: Published application
- Kind: A1
- Application number: 14/574,445
- Filed: 2014-12-18
- Published: 2015-04-16
- Earliest claimed: 2007-08-03
- Assignees: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
- Applicants: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.
- Inventors: Marcello MARCHETTI; Tommaso Iacoangeli; Giovanni Battista Ciottoli; Giuseppe Biondi
- Web page: https://patentgrep.com/patent/US20150105402A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/38: Cellulose; Derivatives thereof
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- A61P 25/36: Opioid-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 249/18: Benzotriazoles
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of allylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A pharmaceutical composition, comprising trazodone hydrochloride and at least one pharmaceutically acceptable excipient, wherein said trazodone hydrochloride comprises less than 15 ppm of alkylating substances.

### Claim 30 (depends on 29)

A pharmaceutical composition according to claim 29, wherein said trazodone hydrochloride comprises less than 10 ppm of alkylating substances.

### Claim 31 (depends on 29)

A pharmaceutical composition according to claim 29, wherein said trazodone hydrochloride comprises less than 2.5 ppm of alkylating substances.

### Claim 32 (depends on 29)

A pharmaceutical composition according to claim 29, wherein said at least one pharmaceutically acceptable excipient is selected from the group consisting of antiadherents, binders, disintegrants, fillers, diluents, flavouring agents, colorants, fluidizers, lubricants, preservatives, moistening agents, absorbents, and sweeteners.

### Claim 33 (depends on 29)

A pharmaceutical composition according to claim 29, wherein said at least one pharmaceutically acceptable excipient is a sugar.

### Claim 34 (depends on 33)

A pharmaceutical composition according to claim 33, wherein said sugar is selected from the group consisting of lactose, glucose and sucrose.

### Claim 35 (depends on 29)

A pharmaceutical composition according to claim 29, wherein said at least one pharmaceutically acceptable excipient is a starch.

### Claim 36 (depends on 35)

A pharmaceutical composition according to claim 35, wherein said starch is selected from the group consisting of maize starch and potato starch.

### Claim 37 (depends on 29)

A pharmaceutical composition according to claim 29, wherein said at least one pharmaceutically acceptable excipient is cellulose or a derivative thereof.

### Claim 38 (depends on 37)

A pharmaceutical composition according to claim 37, wherein said cellulose or a derivative thereof is selected from the group consisting of sodium carboxymethylcellulose, ethylcellulose and cellulose acetate.

### Claim 39 (depends on 29)

A pharmaceutical composition according to claim 29, wherein said at least one pharmaceutically acceptable excipient is a glycol or a polyol.

### Claim 40 (depends on 39)

A pharmaceutical composition according to claim 39, wherein said glycol or polyol is selected from the group consisting of propylene glycols, glycerol, sorbitol, mannitol, and polyethylene glycol.

### Claim 41 (depends on 29)

A pharmaceutical composition according to claim 29, wherein said at least one pharmaceutically acceptable excipient is an ester.

### Claim 42 (depends on 41)

A pharmaceutical composition according to claim 41, wherein said ester is selected from the group consisting of ethyl oleate and ethyl laurate.

### Claim 43 (depends on 29)

A pharmaceutical composition according to claim 29, wherein said at least one pharmaceutically acceptable excipient is an oil.

### Claim 44 (depends on 43)

A pharmaceutical composition according to claim 43, wherein said oil is selected from the group consisting of peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, maize oil, and soya oil.

### Claim 45 (depends on 29)

A pharmaceutical composition according to claim 29, wherein said at least one pharmaceutically acceptable excipient is selected from the group consisting of gum tragacanth, malt, gelatin, talc, cocoa butter, waxes, agar-agar, magnesium hydroxide, aluminium hydroxide, alginic acid, water, isotonic solutions, ethanol, buffer solutions, polyesters, polycarbonates, and polyanhydrides.

### Claim 46 (depends on 29)

A pharmaceutical composition according to claim 29, wherein said composition is for oral or parenteral administration.

### Claim 47 (depends on 46)

A pharmaceutical composition according to claim 46, wherein said composition for oral or parenteral administration is in the form of tablets, lozenges, capsules, solutions, suspensions, dispersions, and syrups.

### Claim 48 (depends on 29)

A pharmaceutical composition according to claim 29, wherein said alkylating substances are selected from the group consisting of 2,2-dichloroethylamine, 1-bromo-3-chloro-propane, N-(3-chlorophenyl)-N′-(3-chloropropyl)-piperazine, 2-(3-chloropropyl)-s-triazolo-[4,3-a]-pyridin-3-one, 3-chloro-N,N′-dichloro-ethyl-aniline, 2-{3-[bis-(2-chloroethyl)-amino]-propyl}-2H-[1,2,4]triaz-olo[4,3-a]pyridin-3-one, 2,2-dibromoethylamine, and 1,3-dichloro-propane.

### Claim 49 (depends on 29)

A pharmaceutical composition according to claim 29, wherein said trazodone hydrochloride comprises less than 1 ppm of each of said alkylating substances.

### Claim 50 (depends on 49)

A pharmaceutical composition according to claim 49, wherein said alkylating substances are selected from the group consisting of 2,2-dichloroethylamine, 1-bromo-3-chloropropane, N-(3-chlorophenyl)-N′-(3-chloropropyl)-piperazine, 2-(3-chloropropyl)-s-triazolo-[4,3-a]-pyridin-3-one, 3-chloro-N,N′-dichloroethylaniline, 2-{3-[bis-(2-chloroethyl)-amino]-propyl}-2H-[1,2,4]triazolo[4,3-a]pyridin-3-one, 2,2-dibromoethylamine, and 1,3-dichloropropane.

### Claim 51 (depends on 49)

A pharmaceutical composition according to claim 49, wherein said alkylating substances are selected from the group consisting of 2,2-dichloroethylamine, 1-bromo-3-chloro-propane, and N-(3-chlorophenyl)-N′-(3-chloropropyl)-piperazine.
